Pregnancy Use

Safety has been investigated in animal tests with no evidence of teratogenicity or any other embryonal toxicity (Rodriguez & Garcia 1994, 1998, Rodriguez et al 1997).

PRACTICE POINTS/PATIENT COUNSELLING

• Policosanol can be considered an efficacious lipid-lowering treatment that may be used in cases where other treatment has been either ineffective or poorly tolerated Numerous, randomised double-blind trials confirm activity.

• Comparative studies with statin drugs have generally produced positive results.

• It does not appear to significantly reduce triglyceride levels; however, it has been used successfully with omega-3 essential fatty acids to reduce total cholesterol levels and triglycerides.

• It is also a safe and potentially useful treatment in claudication.

• Policosanol has significant platelet aggregation inhibitor activity.

• Safety studies indicate that it is well tolerated and has a wide safety margin.

ANSWERS TO PATIENTS' FREQUENTLY ASKED QUESTIONS

What can this supplement do for me?

Policosanol can significantly lower cholesterol levels. Studies suggest this effect is as strong as conventional cholesterol-lowering medications. It also has some blood-thinning activity, is effective in intermittent claudication and can increase total walking distance.

When will it start to work? Policosanol 942

Generally, results are observed after approximately 8 weeks' continuous use. > 2007 Elsevier Australia

Are there any safety issues?

Policosanol has a wide safety margin and is well tolerated. REFERENCES

Alcocer L et al. A comparative study of policosanol versus acipimox in patients with type II hypercholesterolemia. IntJ Tissue React 21.3 (1999): 85-92.

Aleman CL et al. Carcinogenicity of policosanol in Sprague Dawley rats: a 24 month study. Teratog Carcinog Mutagen 14.5 (1994a): 239-49.

Aleman CL et al. A 12-month study of policosanol oral toxicity in Sprague Dawley rats. Toxicol Lett 70.1 (1994b): 77-87.

Arruzazabala ML et al. Comparative study of policosanol, aspirin and the combination therapy policosanol-aspirin on platelet aggregation in healthy volunteers. Pharmacol Res 36.4 (1997): 293-7.

Arruzazabala ML et al. Effect of policosanol on cerebral ischemia in Mongolian gerbils: role of prostacyclin and thromboxane A2. Prostaglandins Leukot Essent Fatty Acids 49.3 (1993a): 695-7.

Arruzazabala ML et al. Effects of Policosanol on platelet aggregation in rats. Thromb Res 69.3 (1993b): 321-7.

Arruzazabala ML et al. Protective effect of policosanol on atherosclerotic lesions in rabbits with exogenous hypercholesterolemia. BrazJ Med Biol Res 33.7 (2000): 835-40.

Arruzazabala ML et al. Antiplatelet effects of policosanol (20 and 40 mg/day) in healthy volunteers and dyslipidaemic patients. Clin Exp Pharmacol Physiol 29.10 (2002): 891-7.

Berthold HK et al. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. JAMA 295.19 (2006): 2262-9.

Carbajal D et al. Effect of policosanol on platelet aggregation and serum levels of arachidonic acid metabolites in healthy volunteers. Prostaglandins Leukot Essent Fatty Acids 58.1 (1998a): 61-4.

Carbajal, D et al. Interaction policosanol-warfarin on bleeding time and thrombosis in rats. Pharmacol Res 38.2 (1998b): 89-91.

Castano G et al. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hype rc hole sterolemic patients. IntJ Clin Pharmacol Res 19.4 (1999a): 105-16.

Castano G et al. A double-blind, placebo-controlled study of the effects of policosanol in patients with intermittent claudication. Angiology 50.2 (1999b): 123-30.

Castano G et al. Effects of policosanol on postmenopausal women with type II hypercholesterolemia. Gynecol Endocrinol 14.3 (2000): 187-95.

Castano G et al. Effects of policosanol in older patients with type II hypercholesterolemia and high coronary risk. J Gerontol A Biol Sei Med Sei 56.3 (2001a): Ml86-92.

Castano G et al. A long-term study of policosanol in the treatment of intermittent claudication. Angiology 52.2 (2001b): 115-25.

Castano G et al. Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia. Drugs Aging 20.2 (2003a): 153-63.

Castano G et al. Effects of policosanol and lovastatin in patients with intermittent claudication: a double-blind comparative pilot study. Angiology 54.1 (2003b): 25-38.

Castano G et al. Concomitant use of policosanol and beta-blockers in older patients. IntJ Clin Pharmacol Res 24.2-3 (2004a): 65-77.

Castano G et al. Effects of policosanol and ticlopidine in patients with intermittent claudication: a double-blinded pilot comparative study. Angiology 55.4 (2004b): 361-71.

Castano G et al. Effects of addition of policosanol to omega-3 fatty acid therapy on the lipid profile of patients with type II hyper cholesterolaemia. Drugs RD 6.4 (2005): 207-19.

Crespo N et al. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependent diabetes mellitus. IntJ Clin Pharmacol Res 19.4 (1999): Policosanol 943

Lower Your Cholesterol In Just 33 Days

Lower Your Cholesterol In Just 33 Days

Discover secrets, myths, truths, lies and strategies for dealing effectively with cholesterol, now and forever! Uncover techniques, remedies and alternative for lowering your cholesterol quickly and significantly in just ONE MONTH! Find insights into the screenings, meanings and numbers involved in lowering cholesterol and the implications, consideration it has for your lifestyle and future!

Get My Free Ebook


Post a comment